
Marion M Mafham

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7450113/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Performance of the UK Prospective Diabetes Study Outcomes Model 2 in a Contemporary UK Type 2 Diabetes Trial Cohort. Value in Health, 2022, 25, 435-442.	0.1	4
2	Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial. European Heart Journal, 2022, 43, 2010-2019.	1.0	18
3	Dexamethasone in Hospitalized Patients with Covid-19. New England Journal of Medicine, 2021, 384, 693-704.	13.9	8,063
4	The RECOVERY trial: cardiovascular implications of a large, simple randomized trial in COVID-19. Cardiovascular Research, 2021, 117, e110-e113.	1.8	3
5	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 499.	3.8	498
6	Streamlined mail-based methods for large randomised trials: lessons learnt from the ASCEND study. Diabetologia, 2020, 63, 898-905.	2.9	3
7	Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. New England Journal of Medicine, 2020, 383, 2030-2040.	13.9	1,013
8	Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, The, 2020, 396, 1345-1352.	6.3	569
9	ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes. American Heart Journal, 2018, 198, 135-144.	1.2	78
10	HARMONY or discord in cardiovascular outcome trials of GLP-1 receptor agonists?. Lancet, The, 2018, 392, 1489-1490.	6.3	5
11	Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. New England Journal of Medicine, 2018, 379, 1529-1539.	13.9	823
12	Effects of nâ^'3 Fatty Acid Supplements in Diabetes Mellitus. New England Journal of Medicine, 2018, 379, 1540-1550.	13.9	510
13	Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease. Hypertension, 2017, 69, 314-322.	1.3	30
14	PCSK9 inhibition: the dawn of a new age in cholesterol lowering?. Diabetologia, 2017, 60, 381-389.	2.9	15